Bristol Myers Squibb Company $BMY Shares Sold by Trek Financial LLC

Trek Financial LLC reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 81.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 6,008 shares of the biopharmaceutical company’s stock after selling 26,966 shares during the quarter. Trek Financial LLC’s holdings in Bristol Myers Squibb were worth $324,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. AG2R LA Mondiale Gestion D Actifs boosted its stake in shares of Bristol Myers Squibb by 6.2% during the 4th quarter. AG2R LA Mondiale Gestion D Actifs now owns 83,057 shares of the biopharmaceutical company’s stock worth $4,480,000 after purchasing an additional 4,879 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 31,330 shares of the biopharmaceutical company’s stock worth $1,690,000 after purchasing an additional 442 shares during the last quarter. Swiss Life Asset Management Ltd boosted its stake in shares of Bristol Myers Squibb by 3.3% during the 4th quarter. Swiss Life Asset Management Ltd now owns 1,180,166 shares of the biopharmaceutical company’s stock worth $63,658,000 after purchasing an additional 37,322 shares during the last quarter. Naples Global Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 4.8% during the 4th quarter. Naples Global Advisors LLC now owns 85,530 shares of the biopharmaceutical company’s stock worth $4,614,000 after purchasing an additional 3,887 shares during the last quarter. Finally, Shoker Investment Counsel Inc. boosted its position in shares of Bristol Myers Squibb by 6.8% in the fourth quarter. Shoker Investment Counsel Inc. now owns 8,634 shares of the biopharmaceutical company’s stock worth $466,000 after acquiring an additional 546 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Bank of America decreased their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Finally, HSBC raised their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Trading Down 0.1%

Shares of BMY stock opened at $56.40 on Thursday. The stock has a market cap of $115.17 billion, a price-to-earnings ratio of 15.84, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm’s 50 day moving average price is $58.83 and its two-hundred day moving average price is $55.25.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.3 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb signed a global collaboration and licensing deal with Hengrui Pharma covering 13 early-stage drug programs, potentially bringing in up to $15.2 billion in milestone payments and strengthening its R&D pipeline. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: The partnership gives Bristol Myers Squibb broader access to promising oncology, hematology, and immunology assets, which could support long-term growth and help offset future revenue losses from older drugs. China’s Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
• Neutral Sentiment: Recent coverage also highlighted that Bristol Myers Squibb beat first-quarter earnings and revenue estimates, which supports the stock’s fundamental story but is less immediate than the Hengrui announcement. Bristol-Myers Squibb Company (BMY) Myers Beats Quarterly Profit Estimates
• Negative Sentiment: Some reports note that BMY shares had been falling in recent sessions, reflecting ongoing investor caution around patent-cliff risks and valuation concerns before the deal news. Bristol-Myers Squibb shares fell for seventh consecutive session

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.